Nexalin Technology, Inc.
NXL- Exchange
- Nasdaq
- Industry
- Electromedical & Electrotherapeutic Apparatus
- SEC CIK
- 0001527352
No open-market purchases or sales by Nexalin Technology, Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $281.6K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −3 vs. previous quarter
- 20
- 13F valueReported value at the end of Q2 2026
- $281.6K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding NXL, Q2 2026
No superinvestor reported holding NXL at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Nexalin Technology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 12, 2025 (view filing)12:58 PM ET | Sep 10 | 2 days | Osser Leonard and 1 other10% Owner, Other: Spouse | SSale | −23.1K | $0.0174 | −$402.81 | –112.8K after | Derivative |
| Mar 13, 2025 (view filing) | Mar 12 | 1 day | Shelton Carolyn HambySr. VP - Quality, Regulatory | PPurchase | +6.00K | $2.20 | +$13.2K | +25.0%30.0K after | |
| Feb 5, 2025 (view filing) | Feb 4 | 1 day | Owens DavidChief Medical Officer | PPurchase | +1.00K | $3.10 | +$3.10K | +0.6%155.8K after | |
| Feb 4, 2025 (view filing) | Feb 4 | Same day | Owens DavidChief Medical Officer | PPurchase | +1.00K | $2.98 | +$2.98K | +0.7%154.8K after | |
| Jan 29, 2025 (view filing) | Jan 28 | 1 day | Owens DavidChief Medical Officer | PPurchase | +1.50K | $2.70 | +$4.05K | +1.0%153.8K after | |
| Jan 24, 2025 (view filing) | Jan 13-23 | 11 daysLate | Owens DavidChief Medical Officer | PPurchase | +3.00K | $2.57 | +$7.70K | +2.0%152.3K after | 2 lots |
| Oct 30, 2024 (view filing) | Oct 28 | 2 days | Owens DavidChief Medical Officer | PPurchase | +500 | $2.19 | +$1.09K | +0.3%148.3K after | |
| Sep 25, 2024 (view filing)5:26 PM ET | Sep 28, 2022 | 728 days | Osser Leonard and 1 otherOther: Spouse | PPurchase | +36.0K | $0.40 | +$14.4K | –136.0K after | AmendedDerivative |
| Aug 15, 2024 (view filing) | Aug 13 | 2 days | Owens DavidChief Medical Officer | PPurchase | +1.00K | $0.95 | +$950 | +0.7%147.8K after | |
| Jul 1, 2024 (view filing) | Jun 28 | 3 days | Owens DavidChief Medical Officer | PPurchase | +1.00K | $1.75 | +$1.75K | +0.7%146.8K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Nexalin Technology, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| PEAK6 LLC | 240,210 | $79.3K | 0.00% | −144,250−37.5% | Reduced |
| Geode Capital Management, LLC | 139,583 | $46.1K | 0.00% | −107,454−43.5% | Reduced |
| Vanguard Capital Management LLC | 126,536 | $41.8K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 75,398 | $24.9K | 0.00% | +75,398 | New |
| Jane Street Group, LLC | 65,497 | $21.6K | 0.00% | +54,987+523.2% | Added |
| Vanguard Fiduciary Trust Co | 51,386 | $17.0K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 32,300 | $10.7K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 26,825 | $8.85K | 0.00% | +4,636+20.9% | Added |
| Kovack Advisors, Inc. | 22,325 | $8.04K | 0.00% | −1,000−4.3% | Reduced |
| Northern Trust Corp | 24,100 | $7.95K | 0.00% | 00.0% | Unchanged |